Final Patient Enrolled in Landmark Alzheimer’s Treatment Trial Targeting...
SYDNEY Actinogen Medical ASX: ACW (‘ACW’ or ‘the Company’) is pleased to announce it has enrolled the final patient into XanADu, its Phase II clinical trial of Xanamem in the treatment of patients...
View Article日印の協業が尿道狭窄の新規治療法を生み出す
東京 (ビジネスワイヤ) — 患者の頬粘膜細胞を使用した男性尿道狭窄の新規治療法として、痛みが比較的少ない方法が患者6人のうち4人で成功したとの報告がなされました。本研究は、日本の生体材料技術の研究者とインドの泌尿器科医のDr Suryaprakash Vaddiの共同研究の成果として、日本泌尿器科学会の公式誌であるInternational Journal of...
View ArticleFDA Approves the ACTPen for Genentech’s Actemra, a Single-Dose, Prefilled...
SOUTH SAN FRANCISCO, Calif. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ACTPen™ 162 mg/0.9 mL,...
View ArticleZymeworks and BeiGene Announce License and Collaboration Agreement for...
VANCOUVER, Canada & BEIJING & CAMBRIDGE, Mass. Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and BeiGene, Ltd. (Nasdaq:...
View ArticleEuropean Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) granted marketing authorization for ALUNBRIG (brigatinib) as a...
View ArticleImpediMed’s SOZO® Digital Health Platform Voted Among Top Five Finalists for...
BRISBANE, Australia & CARLSBAD, Calif. ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status...
View ArticleGI Dynamics Announces Agreement with Apollo Sugar to Study EndoBarrier in India
BOSTON & SYDNEY & HYDERABAD, India GI Dynamics Inc. (ASX: GID), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to...
View Article100,000 Rural Children of Maharashtra to Be Screened for Congenital Heart...
MUMBAI, India HD Medical, Inc. of Silicon Valley announces its participation in the large-scale Divine Mother & Child Health Program (DMCHP) cardiac screening study of 100,000 children at Sri...
View ArticleDr. Reddy’s Laboratories Announces the Launch of Chlorthalidone Tablets, USP...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the...
View ArticleNEOFECT USA to Benefit from Korean IPO Debut
SAN FRANCISCO Korean-American med-tech company NEOFECT today officially began trading on the KOSDAQ, securing more than $17 million in funding. The company, which makes gamified rehabilitation...
View ArticleCelltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a...
INCHEON, South Korea & JERUSALEM Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has...
View ArticleHong Kong High Court Issues Declaratory Orders and Permanent Injunctive...
BEIJING Senior management of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) and the lawful directors of Sinovac Hong Kong, Mr. Yin Weidong and Ms. Wang Nan (“Lawful Directors”),...
View ArticleVisioneering Technologies Inc. Appoints Dr. Peg Achenbach as Vice President,...
ATLANTA To ensure that Eye Care Professionals (ECPs) fully connect with its technology and growing product portfolio, Visioneering Technologies Inc. (VTI), a global company dedicated to improving...
View Article欧盟委员会核准ALUNBRIG® (brigatinib)用于既往接受过克唑替尼治疗的ALK+非小细胞肺癌患者,促进欧洲治疗范式
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502)今天宣布,欧盟委员会(EC)核准ALUNBRIG...
View Article腰痛治療にユニバーサルドナー細胞療法製品を使用するためのSpinalCyteによるIND申請をFDAが承認
ヒューストン (ビジネスワイヤ) — テキサスに拠点を置き、ユニバーサルドナー細胞製品CybroCell™を使用した椎間板髄核再生に傾注する再生医療技術企業のSpinalCyte,...
View Article欧州委員会がクリゾチニブによる前治療歴のあるALK陽性非小細胞肺がん患者の治療薬としてALUNBRIG®(ブリガチニブ)を承認し、欧州における治療パラダイ...
米マサチューセッツ州ケンブリッジ & 大阪 (ビジネスワイヤ) — 武田薬品工業株式会社(TSE:...
View ArticleTakeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) today announced that data from the Phase 3 randomized, TOURMALINE-MM3 study evaluating the effect of single-agent...
View ArticleEuropean Medicines Agency Accepts Extension Marketing Authorisation...
INCHEON, South Korea Celltrion, Inc. (KRX:068270) today announced that the European Medicines Agency (EMA) has accepted for review of the Extension Marketing Authorisation Application for ‘Remsima...
View ArticleLEO Pharma initiates phase 2b clinical studies of topical delgocitinib cream...
BALLERUP, Denmark LEO Pharma A/S, a global leader in medical dermatology, announces today that it has enrolled the first patients in two new phase 2b clinical studies to investigate delgocitinib, a...
View Article